Fourth dose now recommended for cancer patients over 16 The change in ATAGI advice will affect the COVID vaccine recommendations for cancer patients aged 16 and 17 with immediate effect.
Flu return ‘inevitable’ in 2022 After a succession of record lows, newsGP looks at what the traditional flu season might bring this year and the risks of community complacency.
Do current COVID-19 vaccines and treatments neutralise Omicron? New research has looked into a number of medications currently approved for use in Australia, as well as the role of a booster shot against the highly-infectious variant.
HANDI site ‘more complete’ with new patient resources The new resources complement existing resources within HANDI and are aimed at helping GPs provide non-drug intervention-based care.
ATAGI releases clinical information for teen boosters Around 65% of teenagers aged 16 and over are now eligible to receive a COVID booster vaccine.
Online tool aims to guide COVID patients on when to seek medical help Healthdirect’s COVID-19 Symptom Checker is available now and has the potential to ease the burden on general practice and hospitals.
COVID-19 antiviral pills to be reserved primarily for the unvaccinated Despite TGA approval last month, the two new COVID-19 treatments developed by Pfizer and Merck will not be widely available for prescription in the short-term.
Study finds biofilm link to persistent wet cough in children Researchers hope the findings may lead to more effective treatments for protracted bacterial bronchitis and bronchiectasis.
Sufferers of ‘worst pain’ imaginable waiting years for diagnosis Australian experts warn that sufferers of cluster headache face significant delays in diagnosis despite available treatment options.
What does the Omicron sub variant mean for Australia’s pandemic response? Detected in at least 40 countries, including Australia, BA.2 is described as being ‘stealthier’ than the original version of Omicron.